Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug954 | Cognitive Behavioural Group Therapy for Perinatal Anxiety Wiki | 0.50 |
| drug1421 | Essential Oil Blend Wiki | 0.50 |
| drug1033 | Control Blend Wiki | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D030342 | Genetic Diseases, Inborn NIH | 0.50 |
| D001008 | Anxiety Disorders NIH | 0.14 |
| D003141 | Communicable Diseases NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 4 clinical trials
Blood samples from participants who have recovered from COVID-19 infection will be obtained and studied. The goal of the research is to identify antibodies that have been generated by the patient to fight the COVID-19 infection. By identifying the most effective antibodies, scientists can make specific antibodies to use to prevent future coronavirus outbreaks or to treat patients with severe disease.
Description: The blood specimen will be proceeded into peripheral blood mononuclear cells and plasma to be stored for testing. In brief, CD27+ memory B cells that can bind to a SARS-CoV-2 S protein bait will be sorted by flow cytometry and RNA will be extracted to obtain heavy and light chain sequences. Antibody sequences will be annotated using bioinformatics approaches, and candidate sequences will be cloned. Purified antibodies will be characterized and neutralization breadth and potency against SARS-CoV-2 and other related coronaviruses will be assessed using neutralization assays.
Measure: Number of antibodies against coronaviruses isolated and identified from patient samples Time: Up to 12 months after collection visitTo better understand the immune response to SARS-CoV-2 infection, we devised a precision immunology approach to systematically study the immune function of different patient cohorts
Description: Immune response of whole blood stimulation assay with various immune activators will be measured by FACS and multiplex Assay
Measure: Immune response Time: 4 weeks"Background France counted on January 1, 2020, 70,651 people detained, for 61,080 places. Overcrowding in detention is considered as risk factor for infectious diseases transmission, such as respiratory infections. The prison environment represents a confined environment, which could protect prisoners from possible external contamination. If one or more inmates were infected through visiting rooms, officers working in detention, or newly incarcerated people, an epidemic could spread more quickly in the prison community. Thus, few cases of COVID-19 were observed among the subjects in detention with a few weeks delay compared to the free world. However, detention conditions make it more difficult to detect suspicious cases. On the other hand, carrying out diagnostic tests is structurally more difficult to carry out there. Thus, given the plurality of clinical presentations, the non-optimal sensitivity of the SARS-CoV-2 RT-PCR, and the difficulty in carrying out diagnostic tests, it is today difficult to have a precise idea of the number of prisoners having encountered SARS-CoV-2. It is also a population that is not taken into account in the large seroprevalence studies currently conducted in the general population. In order to estimate the number of prisoners exposed to SARS-CoV-2 and in the absence of data currently available in the medical literature, a seroprevalence study in this at risk and little studied population would bring new data to the medical community. Hypothesis In adult subjects living in penal establishments in Ile de France, the seroprevalence of SARS-CoV-2 would be lower compared to the general population. Material and method Open multicenter cross-sectional study carried out in the 11 penal establishments of Ile de France. A sampling of 3,500 inmates stratified over the 16 detention areas concerned will be carried out. The inclusion criteria will be detained subjects who have expressed their consent to participate in the research, aged 18 to 80 years. Each selected detainee will be invited to the health unit to perform a venous blood test for anti-SARS-CoV-2 antibodies. The goal is to take 2,500 blood samples (30% expected refusal rate). Each sample will be analyzed in the virology laboratory at P. Brousse hospital. Expected results Obtain an assessment of the seroprevalence of SARS-CoV-2 in prisons to determine the exposure of detained persons. This assessment will make it possible to undertake public health actions and to propose the implementation of group protection measures such as vaccination if this is soon available.
Description: It's obtained from ELISA tests carried out on blood samples. A subject will be considered to have been infected with the SARS-CoV-2 virus if anti-SARS-CoV-2 IgGs are detected in his blood sample.
Measure: Determination of the immunological parameters (Immunoglobins G) of the SARS-CoV-2 infection Time: 7 daysDescription: (fever or feeling of fever, headache, muscle aches and / or pain, cough, unusual breathing and / or shortness of breath, chest pain and / or tightness, rhinorrhea, nausea and / or vomiting, diarrhea, anosmia , ageusia, unusual tiredness), onset of hospitalization for COVID-19, onset of hospitalization in intensive care for COVID-19
Measure: Symptoms suggestive of COVID-19 Time: 7 daysDescription: age, smoking, cardiovascular history, diabetes, chronic respiratory disease, renal failure, active cancer, immunosuppression, hepatic cirrhosis , obesity, splenectomy, acute chest syndrome, sickle cell syndrome, taking chlorpromazine, number of inmates in the same cell, ward for vulnerable people, date of incarceration.
Measure: Factors assumed to be related to infection with SARS-CoV-2 and the occurrence of moderate to severe forms of COVID-19 Time: 7 daysUPTIDER is a prospective, interventional, non-Investigational Medicinal Product (non-IMP), non-commercial, single centre post-mortem tissue donation program for metastatic breast cancer patients or patients with a germline pathogenic variant with a moderate to high lifetime risk of breast cancer and at least one malignancy at time of death. The overarching objective of UPTIDER is (i) to unravel metastatic breast cancer evolution, biology, heterogeneity and treatment resistance and (ii) to assess pathogenicity and tumour biology in hereditary cancer syndromes with a high lifetime risk of breast cancer; both through extensive post-mortem multi-level and multi-region sample analysis.
Description: Should be equal to or above 50%
Measure: Percentage of patients consenting to participate in the pilot phase Time: BaselineDescription: Should be equal to or less than 12h
Measure: Median time elapsed between moment of death and start of the autopsy Time: During autopsyDescription: Should be equal to or less than 8h
Measure: Median time elapsed between collection of first and last sample Time: During autopsyDescription: Should be equal to or more than 75%
Measure: Percentage of metastatic organs sampled Time: During autopsyDescription: A260/A280 ratio
Measure: Percentage of samples with sufficient quality of DNA extracted Time: During autopsyDescription: RNA integrity number (RIN)
Measure: Percentage of samples with sufficient quality of RNA extracted Time: During autopsyDescription: Standard histopathological review
Measure: Concordance between TILs and clinical response to treatment Time: During autopsyDescription: RNA sequencing
Measure: Rate of T cell exhaustion Time: During autopsyDescription: Whole exome sequencing
Measure: Number of mutations in each tumor lesion Time: During autopsyDescription: Whole exome sequencing
Measure: Type of mutations in each tumor lesion Time: During autopsyDescription: Standard histopathological review
Measure: Percentage of Tumour Infiltrating Lymphocytes (TILs) Time: During autopsyAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports